Cytomegalovirus Whole Blood

Cytomegalovirus Whole Blood for Infectious Disease and Viral Immunology Research

Fresh Cytomegalovirus Whole Blood is collected from IRB-consented donors with documented cytomegalovirus (CMV) infection or CMV seropositivity, and shipped same-day to preserve cell viability, viral nucleic acid, and RNA integrity. CMV is a betaherpesvirus that establishes lifelong latency after primary infection, so this is an infectious disease product: the immune features it supports are the host response to a persistent virus, not autoimmunity.

CMV Biology and Why Whole Blood

  • CMV establishes lifelong latency after primary infection, with the myeloid lineage – CD34+ progenitors and monocytes – serving as the principal latent reservoir, and reactivation occurring on differentiation or immune suppression.
  • Primary infection is usually subclinical in immunocompetent hosts but causes significant disease in transplant recipients, people with advanced HIV, and congenitally infected infants, making CMV a major target for antiviral and vaccine development.
  • CMV drives an unusually large and durable adaptive response: CD8+ T-cell memory inflation can occupy a substantial fraction of the circulating T-cell repertoire in seropositive donors, and CMV-specific responses are commonly measured against pp65 and IE-1 antigens.
  • CMV seropositivity is associated with expansion of adaptive or memory-like NK cells characterised by NKG2C expression and altered signalling-molecule profiles, an important consideration when sourcing donors for NK-cell work.
  • Viral DNA in whole blood is the standard analyte for viral load quantification by real-time PCR, and whole blood also retains the latently infected myeloid compartment needed for reservoir and reactivation studies.
  • Whole blood preserves leukocytes together with the plasma compartment, supporting parallel virological, serological, transcriptomic, and cellular immunology readouts from a single specimen.

Donor Stratification Available

  • Infection stage: latent seropositive versus documented active infection or reactivation
  • Serostatus detail: CMV IgG positive, IgM positive, or IgG avidity results where available
  • Immune status: immunocompetent versus immunosuppressed, transplant recipient, or immunodeficient
  • Antiviral treatment status, including ganciclovir/valganciclovir or letermovir exposure
  • Co-infection status, including EBV and HIV serology where documented
  • Age band, sex, and HLA type where typing is available
  • Matched healthy controls available, including CMV-seronegative donors

Product Features

  • Fresh whole blood from donors with documented CMV infection or seropositivity
  • Custom tubes and anticoagulants available, including RNA-stabilising collection tubes
  • Collected and shipped same-day for maximum freshness
  • Standard and custom volumes
  • IRB-approved protocols and electronic informed consent
  • Research Use Only (RUO)

De-identified Donor Data

  • Confirmed cytomegalovirus infection or seropositivity
  • Demographic details: age, sex assigned at birth, ethnicity
  • Medical history including allergies and infectious disease status
  • Serology results, antiviral treatment, and immune status where documented
  • Additional CMV-specific metadata available on request

Applications

  • CMV viral load quantification and PCR assay development or validation
  • Immunophenotyping of CMV-associated T-cell and adaptive NK-cell compartments by flow cytometry
  • Antigen-specific T-cell assays against pp65 and IE-1, including ELISpot and intracellular cytokine staining
  • Latency and reactivation studies using the myeloid reservoir
  • Host transcriptomic response profiling in stabilised whole blood
  • Serological assay development, including IgG, IgM, and avidity testing in the paired plasma fraction
  • Antiviral drug susceptibility and resistance-mutation research
  • Donor screening support for CMV-matched or CMV-naive cell therapy and NK-cell research programmes

Other Cytomegalovirus Specimen Types

Compliance and Quality Assurance

  • IRB-approved protocols and electronic informed consent
  • 21 CFR Part 11-compliant e-consent
  • HIPAA-compliant data management

Ordering & Customization

Cytomegalovirus whole blood is available in a range of standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare donor availability across conditions, visit our human whole blood page.

Whole Blood

Frequently Asked Questions

Showing 1–12 of 26 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Whole Blood cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information